In a recent paper, Olof Eriksson (associate professor at Uppsala University and Director, PET Imaging at Antaros Medical), Lars Johansson (CSO at Antaros Medical), Stefan Pierrou (Director, Clinical Trial Management at Antaros Medical) and co-authors, present an optimized and simplified positron emission tomography (PET) scanning protocol of [68Ga]Exendin4, to enable reproducible imaging of the glucagon like peptide-1 (GLP-1) receptor in human pancreas.
This important work to develop a PET tracer for the GLP-1 receptor contributes to the pharmacokinetic understanding of incretin agonists in the search for novel therapeutics in metabolic disorders. Further, this PET tracer forms a powerful tool set together with Antaros Medical proprietary PET tracers for the gastric inhibitory polypeptide (GIP) and glucagon receptors for tailoring solutions measuring receptor occupancy of both bi- and trimodal incretin agonists. This PET-tracer tool set can provide data to help set dosing and to provide evidence that the investigated drug is hitting several targets as intended – including understanding the overlapping pharmacology of activating the different incretin receptors with multi-agonist peptides. This is an important platform for moving new metabolic including anti-diabetic treatments forward.
Find the article here
Title: Glucagon Like Peptide-1 receptor imaging in individuals with Type 2 Diabetes
Authors: Eriksson O, Velikyan I, Haack T, Bossart M, Laitinen I, Larsen PJ, Berglund JE, Antoni G, Johansson L, Pierrou S, Tillner J, Wagner M